Annexin 1 induced by anti-inflammatory drugs binds to NF-κB and inhibits its activation: Anticancer effects in vitro and in vivo

Cancer Research

Volumn 70, Issue 6, 2010, Pages 2379-2388

  Zhang, Zhiquan ^a   Huang, Liqun ^a   Zhao, Wenping ^a   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DEXAMETHASONE; DNA; GLUCOCORTICOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOCORTIN 1; NONSTEROID ANTIINFLAMMATORY AGENT; OLIGOPEPTIDE; TRIPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CARCINOGENESIS; CELL COMMUNICATION; CELL GROWTH; CELL PH; CELL STRAIN SW 480; COLON CANCER; CONTROLLED STUDY; CULTURE MEDIUM; DNA BINDING; DRUG BINDING; DRUG POTENCY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTESTINE MUCOSA; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANNEXIN A1; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; CELL GROWTH PROCESSES; CELL LINE, TUMOR; COLONIC NEOPLASMS; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NF-KAPPA B; TRANSCRIPTION FACTOR RELA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950235551     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4204     Document Type: Article

References (27)

1. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-899
2. Rigas B. The use of nitric oxide-donating nonsteroidal anti-inflammatory drugs in the chemoprevention of colorectal neoplasia. Curr Opin Gastroenterol 2007;23:55-59
3. Williams JL, Ji P, Ouyang N, Liu X, Rigas B. NO-donating aspirin inhibits the activation of NF-κB in human cancer cell lines and Min mice. Carcinogenesis 2008;29:390-397
4. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-436
5. Zhang Z, Rigas B. NF-κB, inflammation and pancreatic carcinogenesis: NF-κB as a chemoprevention target (review). Int J Oncol 2006; 29:185-192
6. Wong ET, Tergaonkar V. Roles of NF-κB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 2009;116: 451-465
7. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009;27:693-733.
8. Holcomb B, Yip-Schneider M, Schmidt CM. The role of nuclear factor κB in pancreatic cancer and the clinical applications of targeted therapy. Pancreas 2008;36:225-235
9. Schmitz R, Stanelle J, Hansmann ML, Kuppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol 2009;4:151-174
10. D'Acquisto F, Perretti M, Flower RJ. Annexin-A1: a pivotal regulator of the innate and adaptive immune systems. Br J Pharmacol 2008; 155:152-169
11. Kamal AM, Flower RJ, Perretti M. An overview of the effects of annexin 1 on cells involved in the inflammatory process. Mem Inst Oswaldo Cruz 2005;100 Suppl 1:39-47.
12. Mussunoor S, Murray GI. The role of annexins in tumour development and progression. J Pathol 2008;216:131-140
13. Buckingham JC, John CD, Solito E, et al. Annexin 1, glucocorticoids, and the neuroendocrine-immune interface. Ann N Y Acad Sci 2006; 1088:396-409.
14. Perretti M, D'Acquisto F. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nat Rev Immunol 2009;9:62-70.
15. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.
16. Rigas B, Kozoni V. The novel phenylester anticancer compounds: study of a derivative of aspirin (phosphoaspirin). Int J Oncol 2008; 32:97-100.
17. Schimmer BP, Parker KL. Adrenocortical steroids and their synthetic analogs. In: Hardman JG, Limbird LE, editors. Goodman & Gillman's the pharmacological basis of therapeutics. New York: McGraw Hill; 2001, p. 1649-1677
18. Zhao W, Mackenzie GG, Murray OT, Zhang Z, Rigas B. Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis 2009;30:512-519
19. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001;61:3285-3289
20. Lipkin M, Yang K, Edelmann W, et al. Preclinical mouse models for cancer chemoprevention studies. Ann N Y Acad Sci 1999; 889:14-19
21. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC (Min/+)) mice. Biochem Biophys Res Commun 2004;313:784-788
22. Scannell M, Flanagan MB, deStefani A, et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 2007;178: 4595-4605
23. Shen HM, Tergaonkar V. NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009;14: 348-363
24. Miskolci V, Rollins J, Vu HY, Ghosh CC, Davidson D, Vancurova I. NFκB is persistently activated in continuously stimulated human neutrophils. Mol Med 2007;13:134-142
25. La M, D'Amico M, Bandiera S, et al. Annexin 1 peptides protect against experimental myocardial ischemia-reperfusion: analysis of their mechanism of action. FASEB J 2001;15:2247-2256
26. Vancurova I, Bellani P, Davidson D. Activation of nuclear factor-κB and its suppression by dexamethasone in polymorphonuclear leukocytes: newborn versus adult. Pediatr Res 2001;49:257-262
27. Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009;373:1905-1917